As of 2025-01-21, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -11.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 428.19 mil USD. TBPH's TTM EBITDA according to its financial statements is -37.80 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.9x - 7.9x | 6.8x |
| Forward P/E multiples | 5.0x - 10.6x | 8.2x |
| Fair Price | (3.97) - (6.17) | (5.89) |
| Upside | -146.3% - -171.9% | -168.7% |
| Date | EV/EBITDA |
| 2025-01-17 | -11.33 |
| 2025-01-16 | -11.15 |
| 2025-01-15 | -11.37 |
| 2025-01-14 | -11.26 |
| 2025-01-13 | -11.32 |
| 2025-01-10 | -11.59 |
| 2025-01-08 | -11.94 |
| 2025-01-07 | -12.20 |
| 2025-01-06 | -12.12 |
| 2025-01-03 | -12.28 |
| 2025-01-02 | -12.24 |
| 2024-12-31 | -12.41 |
| 2024-12-30 | -12.49 |
| 2024-12-27 | -12.64 |
| 2024-12-26 | -12.99 |
| 2024-12-24 | -12.98 |
| 2024-12-23 | -12.90 |
| 2024-12-20 | -12.64 |
| 2024-12-19 | -12.82 |
| 2024-12-18 | -12.80 |
| 2024-12-17 | -13.12 |
| 2024-12-16 | -12.92 |
| 2024-12-13 | -13.02 |
| 2024-12-12 | -13.01 |
| 2024-12-11 | -13.23 |
| 2024-12-10 | -13.28 |
| 2024-12-09 | -13.16 |
| 2024-12-06 | -13.02 |
| 2024-12-05 | -12.97 |
| 2024-12-04 | -12.64 |
| 2024-12-03 | -12.97 |
| 2024-12-02 | -12.45 |
| 2024-11-29 | -12.20 |
| 2024-11-27 | -12.42 |
| 2024-11-26 | -12.19 |
| 2024-11-25 | -12.49 |
| 2024-11-22 | -12.49 |
| 2024-11-21 | -12.67 |
| 2024-11-20 | -13.14 |
| 2024-11-19 | -13.07 |
| 2024-11-18 | -12.51 |
| 2024-11-15 | -12.55 |
| 2024-11-14 | -12.62 |
| 2024-11-13 | -12.76 |
| 2024-11-12 | -11.76 |
| 2024-11-11 | -11.98 |
| 2024-11-08 | -11.80 |
| 2024-11-07 | -11.55 |
| 2024-11-06 | -11.50 |
| 2024-11-05 | -10.93 |